Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-l-lysine in carboxymethyl cellulose [Poly(I,C)-LC]

Paul L. Black, Diethelm Hartmann, Robin Pennington, Hamblin Phillips, Mark Schneider, Henry R. Tribble, James E Talmadge

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We examined the immunomodulatory and therapeutic activities of poly(I,C-LC. Mice received a subcutaneous (s.c.) injection of sufficient numbers of MBL-2 lymphoma cells to produce in 1 week either a high or low tumor burden. A week after tumor cell injection, poly(I,C)-LC treatment was initieated; the agent was administered intraperitoneally (i.p.) at 5 mg/kg twice a week or at 2.5 or 0.5 mg/kg every day or as an intravenous (i.v.) injection at 0.5, 0.05, or 0.005 mg/kg three times a week. Poly(I,C)-LC treatment significantly increased antitumor effector cell functions in a variey of organs (including spleen, lungs, and peritoneum), as shown by increased killing of MBL-2 cells in vitro and increased tumor cell killing by natural killer cells and macrophages. Furthermore, prolongation of survival correlated with peritoneal macrophage tumoricidal activity when poly(I,C)-LC was given i.p. and with pulmonary effector cell function (including natural killer, cytolytic T-lymphocyte and macrophage tumoricidal activity) when the agent was administered i.v.

Original languageEnglish (US)
Pages (from-to)1341-1353
Number of pages13
JournalInternational Journal of Immunopharmacology
Volume14
Issue number8
DOIs
StatePublished - Nov 1992

Fingerprint

Poly I-C
Carboxymethylcellulose Sodium
Tumor Burden
Lysine
Macrophages
Lung
Peritoneum
Peritoneal Macrophages
Subcutaneous Injections
Intravenous Injections
Natural Killer Cells
polyriboinosinic-polyribocytidylic acid
Lymphoma
Neoplasms
Therapeutics
Spleen
T-Lymphocytes
Injections

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-l-lysine in carboxymethyl cellulose [Poly(I,C)-LC]. / Black, Paul L.; Hartmann, Diethelm; Pennington, Robin; Phillips, Hamblin; Schneider, Mark; Tribble, Henry R.; Talmadge, James E.

In: International Journal of Immunopharmacology, Vol. 14, No. 8, 11.1992, p. 1341-1353.

Research output: Contribution to journalArticle

@article{882bd0a8851f42d0a09c6fb271f25a11,
title = "Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-l-lysine in carboxymethyl cellulose [Poly(I,C)-LC]",
abstract = "We examined the immunomodulatory and therapeutic activities of poly(I,C-LC. Mice received a subcutaneous (s.c.) injection of sufficient numbers of MBL-2 lymphoma cells to produce in 1 week either a high or low tumor burden. A week after tumor cell injection, poly(I,C)-LC treatment was initieated; the agent was administered intraperitoneally (i.p.) at 5 mg/kg twice a week or at 2.5 or 0.5 mg/kg every day or as an intravenous (i.v.) injection at 0.5, 0.05, or 0.005 mg/kg three times a week. Poly(I,C)-LC treatment significantly increased antitumor effector cell functions in a variey of organs (including spleen, lungs, and peritoneum), as shown by increased killing of MBL-2 cells in vitro and increased tumor cell killing by natural killer cells and macrophages. Furthermore, prolongation of survival correlated with peritoneal macrophage tumoricidal activity when poly(I,C)-LC was given i.p. and with pulmonary effector cell function (including natural killer, cytolytic T-lymphocyte and macrophage tumoricidal activity) when the agent was administered i.v.",
author = "Black, {Paul L.} and Diethelm Hartmann and Robin Pennington and Hamblin Phillips and Mark Schneider and Tribble, {Henry R.} and Talmadge, {James E}",
year = "1992",
month = "11",
doi = "10.1016/0192-0561(92)90005-6",
language = "English (US)",
volume = "14",
pages = "1341--1353",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-l-lysine in carboxymethyl cellulose [Poly(I,C)-LC]

AU - Black, Paul L.

AU - Hartmann, Diethelm

AU - Pennington, Robin

AU - Phillips, Hamblin

AU - Schneider, Mark

AU - Tribble, Henry R.

AU - Talmadge, James E

PY - 1992/11

Y1 - 1992/11

N2 - We examined the immunomodulatory and therapeutic activities of poly(I,C-LC. Mice received a subcutaneous (s.c.) injection of sufficient numbers of MBL-2 lymphoma cells to produce in 1 week either a high or low tumor burden. A week after tumor cell injection, poly(I,C)-LC treatment was initieated; the agent was administered intraperitoneally (i.p.) at 5 mg/kg twice a week or at 2.5 or 0.5 mg/kg every day or as an intravenous (i.v.) injection at 0.5, 0.05, or 0.005 mg/kg three times a week. Poly(I,C)-LC treatment significantly increased antitumor effector cell functions in a variey of organs (including spleen, lungs, and peritoneum), as shown by increased killing of MBL-2 cells in vitro and increased tumor cell killing by natural killer cells and macrophages. Furthermore, prolongation of survival correlated with peritoneal macrophage tumoricidal activity when poly(I,C)-LC was given i.p. and with pulmonary effector cell function (including natural killer, cytolytic T-lymphocyte and macrophage tumoricidal activity) when the agent was administered i.v.

AB - We examined the immunomodulatory and therapeutic activities of poly(I,C-LC. Mice received a subcutaneous (s.c.) injection of sufficient numbers of MBL-2 lymphoma cells to produce in 1 week either a high or low tumor burden. A week after tumor cell injection, poly(I,C)-LC treatment was initieated; the agent was administered intraperitoneally (i.p.) at 5 mg/kg twice a week or at 2.5 or 0.5 mg/kg every day or as an intravenous (i.v.) injection at 0.5, 0.05, or 0.005 mg/kg three times a week. Poly(I,C)-LC treatment significantly increased antitumor effector cell functions in a variey of organs (including spleen, lungs, and peritoneum), as shown by increased killing of MBL-2 cells in vitro and increased tumor cell killing by natural killer cells and macrophages. Furthermore, prolongation of survival correlated with peritoneal macrophage tumoricidal activity when poly(I,C)-LC was given i.p. and with pulmonary effector cell function (including natural killer, cytolytic T-lymphocyte and macrophage tumoricidal activity) when the agent was administered i.v.

UR - http://www.scopus.com/inward/record.url?scp=0026456687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026456687&partnerID=8YFLogxK

U2 - 10.1016/0192-0561(92)90005-6

DO - 10.1016/0192-0561(92)90005-6

M3 - Article

C2 - 1464467

AN - SCOPUS:0026456687

VL - 14

SP - 1341

EP - 1353

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 8

ER -